Influenza (the flu) is a contagious respiratory illness caused by influenza viruses. It can cause mild to severe illness, and at times can lead to death. The best way to prevent the flu is by getting a flu vaccination each year. Every year in the United States, on average 5% to 20% of the population gets the flu; more than 200,000 people are hospitalized from flu complications, and; about 36,000 people die from flu-related causes. Some people, such as older people, young children, and people with certain health conditions, are at high risk for serious flu complications.
Jacqueline Kimmey speaks to AZoLifeSciences about her research into bacterial pneumonia and the genes that drive its spread from the lungs into the blood.
MIT chemists have determined the molecular structure of a protein found in the SARS-CoV-2 virus. This protein, called the envelope protein E, forms a cation-selective channel and plays a key role in the virus's ability to replicate itself and stimulate the host cell's inflammation response.
The vast majority of individuals infected with mild-to-moderate COVID 19 mount a robust antibody response that is relatively stable for at least five months, according to research conducted at the Icahn School of Medicine at Mount Sinai and published October 28, in the journal Science.
For the first time, researchers have successfully created airway basal stem cells in vitro from induced pluripotent stem cells by reprogramming blood cells taken from patients.
To identify new potential therapeutic targets for SARS-CoV-2, a team of scientists at the New York Genome Center, New York University, and the Icahn School of Medicine at Mount Sinai, performed a genome-scale, loss-of-function CRISPR screen to systematically knockout all genes in the human genome.
New research from an immunology team at the University of Chicago may shed light on the challenges of developing a universal flu vaccine that would provide long-lasting and broad protection against influenza viruses.
A team of Duke University researchers has developed a lab-grown living lung model that mimics the tiny air sacs of the lungs where coronavirus infection and serious lung damage take place. This advance has enabled them to watch the battle between the SARS-CoV-2 coronavirus and lung cells at the finest molecular scale.
SPIN (SPermidin and eugenol INtegrator for the contrasting incidence of coronavirus in EU population) is a European project powered by EIT Food that is currently developing a dietary supplement supporting the function of the immune system in the fight against SARS-CoV-2 infections in the population at high risk.
Chemist Mahmoud Moradi has received a $422,579 grant from the National Institutes of Health to advance his work modeling hemagglutinin, the critical protein of the influenza virus.
A large international consortium of almost 200 researchers from 14 leading institutions in six countries has studied three different coronaviruses - SARS-CoV-1, SARS-CoV-2, and MERS-CoV - with the aim of finding vulnerabilities shared by these three pathogens.
SARS-CoV-2 continues to cause an ongoing pandemic as of October 2020, with over 35 million reported cases and over 1 million deaths around the world.
Virologists at the KU Leuven Rega Institute have been working on two lines of SARS-CoV-2 research: searching for a vaccine to prevent infection, and testing existing drugs to see which one can reduce the amount of virus in infected people.
Researchers at CSIRO, Australia's national science agency, have found that SARS-CoV-2, the virus responsible for COVID-19, can survive for up to 28 days on common surfaces including banknotes, glass - such as that found on mobile phone screens - and stainless steel.
Gene therapy offers an excellent potential for treating specific types of genetic defects and cancer, immunological diseases, infections, and wounds.
There is great potential in gene therapy for treating certain types of cancer and genetic defects, immunological diseases, wounds and infections.
A number of vaccines contain ingredients known as adjuvants that make them more effective by triggering a more powerful immune response.
Scientists have discovered a new cellular pathway that can be targeted with a naturally occurring medication to activate the regeneration of lung tissue.
Researchers have identified two antibodies that protect mice against lethal infections of influenza B virus, report scientists at Washington University School of Medicine in St. Louis and Icahn School of Medicine at Mount Sinai.
As Americans begin pulling up their sleeves for an annual flu vaccine, researchers at the University of Wisconsin-Madison have provided new insights into an alternative vaccine approach that provides broader protection against seasonal influenza.
Using innovative computer-based approaches, researchers have developed protein inhibitors that block the interaction between the SARS-CoV-2 virus and human cell receptor ACE2.